Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients-Reference-Cited by-同舟云学术

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients

Published:2020-07-08 Issue:9 Volume:11 Page:2406-2430
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Song Peng¹^ORCID,Zhang Dingding²^ORCID,Cui Xiaoxia¹^ORCID,Zhang Li¹

Affiliation:

1. Department of Respiratory Medicine, Peking Union Medical College HospitalChinese Academy of Medical Science & Peking Union Medical College Beijing China

2. Central Research Laboratory,Peking Union Medical College HospitalChinese Academy of Medical Science & Peking Union Medical College Beijing China

Funder

CAMS Innovation Fund for Medical Sciences

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13541

Reference149 articles.

1. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

2. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

3. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

4. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

5. Pembrolizumab versus Ipilimumab in Advanced Melanoma

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis;Frontiers in Oncology;2024-07-15

2. Real‐world experience of immune checkpoint inhibitors in patients with solid tumours in the Top End of the Northern Territory, Australia from 2016 to 2021: a retrospective observational cohort study;Internal Medicine Journal;2024-07-05

3. Cardiac irradiation combined with an anti-Programmed cell death protein 1 antibody induces time-dependent myocardial injury by regulating the HMGB1/NF-κB pathway;2024-06-14

4. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review;Pharmaceuticals;2024-04-14

5. Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis;Case Reports in Oncology;2024-04-09